Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a 6.08% increase in stock price, currently at HKD 10.82, with a trading volume of HKD 14.2577 million following the acceptance of their IND application for JSKN033 by the National Medical Products Administration (NMPA) [1][4]. Group 1 - Corning Jereh Pharmaceutical-B announced the acceptance of their IND application for JSKN033, a high-concentration subcutaneous compound formulation combining HER2 bispecific antibody-drug conjugates (ADCs) and PDL1 immune checkpoint inhibitors for the first-line treatment of advanced cervical cancer [1][4]. - The JSKN033-202 trial is an open-label, multi-center, Phase II clinical trial aimed at evaluating the safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics of JSKN033 in combination with platinum-based chemotherapy, with or without Bevacizumab, for patients with advanced cervical cancer [1][4]. - All patients in the trial will receive treatment with JSKN033 in combination with either Cisplatin or Carboplatin, with the choice of platinum drug and the inclusion of Bevacizumab determined by the researchers based on individual patient circumstances [1][4].
康宁杰瑞制药-B现涨超6% 近日SKN033的一项II期临床试验IND申请获受理